Halofuginone improves muscle-cell survival in muscular dystrophies

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 7, 2014, Pages 1339-1347

  Bodanovsky, Anna ^a   Guttman, Noga ^a   Barzilai Tutsch, Hila ^a   Genin, Ola ^b   Levy, Oshrat ^b   Pines, Mark ^b   Halevy, Orna ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b VOLCANI CENTER   (Israel)

Author keywords

Apoptosis; Halofuginone; Muscular dystrophy; Myofiber; Myofibroblast; Satellite cell

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HALOFUGINONE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN BAX; PROTEIN BCL 2; STAUROSPORINE; TRANSCRIPTION FACTOR PAX7; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; BAX PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED FUNCTION OXIDASE; PAX7 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; PIPERIDINE DERIVATIVE; PROTEIN BAK; QUINAZOLINONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DIAPHRAGM; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; MACROPHAGE; MOTOR COORDINATION; MOUSE; MUSCLE CELL; MUSCLE FIBRIL; MYOBLAST; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TASK PERFORMANCE; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; PRIMARY CELL CULTURE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ACTINS; ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; DIAPHRAGM; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MICE; MICE, INBRED MDX; MIXED FUNCTION OXYGENASES; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; MYOFIBRILS; PAX7 TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERIDINES; PRIMARY CELL CULTURE; QUINAZOLINONES; SIGNAL TRANSDUCTION;

EID: 84898849125     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.03.025     Document Type: Article

References (69)

1. Collins C.A. Satellite cell self-renewal. Curr. Opin. Pharmacol. 2006, 6:301-306.
2. Yablonka-Reuveni Z. The skeletal muscle satellite cell: still young and fascinating at 50. J. Histochem. Cytochem. 2011, 59:1041-1059.
3. Sandri M., Carraro U. Apoptosis of skeletal muscles during development and disease. Int. J. Biochem. Cell Biol. 1999, 31:1373-1390.
4. Fernando P., Kelly J.F., Balazsi K., Slack R.S., Megeney L.A. Caspase 3 activity is required for skeletal muscle differentiation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11025-11030.
5. Dominov J.A., Kravetz A.J., Ardelt M., Kostek C.A., Beermann M.L., Miller J.B. Muscle-specific BCL2 expression ameliorates muscle disease in laminin alpha2-deficient, but not in dystrophin-deficient, mice. Hum. Mol. Genet. 2005, 14:1029-1040.
6. Hirai H., Verma M., Watanabe S., Tastad C., Asakura Y., Asakura A. MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3. J. Cell Biol. 2010, 191:347-365.
7. Guo B.S., Cheung K.K., Yeung S.S., Zhang B.T., Yeung E.W. Electrical stimulation influences satellite cell proliferation and apoptosis in unloading-induced muscle atrophy in mice. PLoS One 2012, 7:e30348.
8. Rezk B.M., Yoshida T., Semprun-Prieto L., Higashi Y., Sukhanov S., Delafontaine P. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One 2012, 7:e30276.
9. Chelh I., Meunier B., Picard B., Reecy M.J., Chevalier C., Hocquette J.F., Cassar-Malek I. Molecular profiles of Quadriceps muscle in myostatin-null mice reveal PI3K and apoptotic pathways as myostatin targets. BMC Genomics 2009, 10:196.
10. Fulle S., Centurione L., Mancinelli R., Sancilio S., Manzoli F.A., Di Pietro R. Stem cell ageing and apoptosis. Curr. Pharm. Des. 2012, 18:1694-1717.
11. Michael I., Lewis M.D. Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002, 166:434-436.
12. Tews D.S. Apoptosis and muscle fibre loss in neuromuscular disorders. Neuromuscul. Disord. 2002, 12:613-622.
13. Tews D.S. Muscle-fiber apoptosis in neuromuscular diseases. Muscle Nerve 2005, 32:443-458.
14. Tidball J.G., Albrecht D.E., Lokensgar B.E., Spencer M.J. Apoptosis precedes necrosis of dystrophin-deficient muscle. J. Cell Sci. 1995, 108:2197-2204.
15. Sandri M., Minetti C., Pedemonte M., Carraro U. Apoptotic myonuclei in human Duchenne muscular dystrophy. Lab. Invest. 1998, 78:1005-1016.
16. Coulton G.R., Rogers B., Strutt P., Skynner M.J., Watt D.J. In situ localization of single-stranded DNA breaks in nuclei of a subpopulation of cells within regenerating skeletal muscle of the dystrophic mdx mouse. J. Cell Sci. 1992, 102:653-662.
17. Tews D.S., Goebel H.H. Apoptosis-related proteins in skeletal muscle fibers of spinal muscular atrophy. J. Neuropathol. Exp. Neurol. 1997, 56:150-156.
18. Hadj Salem I., Kamoun F., Louhichi N., Trigui M., Triki C., Fakhfakh F. Impact of single-nucleotide polymorphisms at the TP53-binding and responsive promoter region of BCL2 gene in modulating the phenotypic variability of LGMD2C patients. Mol. Biol. Rep. 2012, 39:7479-7486.
19. Girgenrath M., Dominov J.A., Kostek C.A., Miller J.B. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J. Clin. Invest. 2004, 114:1635-1639.
20. Girgenrath M., Beermann M.L., Vishnudas V.K., Homma S., Miller J.B. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol. 2009, 65:47-56.
21. Levi-Schaffer F., Nagler A., Slavin S., Knopov V., Pinesygi M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J. Invest. Dermatol. 1996, 106:4-8.
22. Pines M., Domb A., Ohana M., Inbar J., Genina O., Alexiev R., Nagler A. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem. Pharmacol. 2001, 62:1221-1227.
23. Pines M. Inhibition of TGFβ signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 2009, 38:427-435.
24. Pines M. Targeting TGFβ signaling to inhibit fibroblasts activation as a therapy for fibrosis and cancer. Expert Opin. Drug Discov. 2008, 3:11-20.
25. Turgeman T., Huebner K., Anderson J., Genin O., Nagler A., Halevy O., Pines M. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul. Disord. 2008, 18:857-868.
26. Nevo Y., Halevy O., Genin O., Moshe I., Turgeman T., Harel M., Biton E., Rief S., Pines M. Fibrosis inhibition and muscle characteristics improvement in laminin-α2 deficient mice. Muscle Nerve 2010, 42:218-229.
27. Halevy O., Pines M. Halofuginone and muscular dystrophy. Histol. Histopathol. 2011, 26:135-146.
28. Halevy O., Genin O., Barzilai-Tutsch H., Pima Y., Levi O., Moshe I., Pines M. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol. Histopathol. 2013, 28:211-226.
29. Huebner K.D., Jassal D.S., Halevy O., Pines M., Anderson J.E. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1550-H1561.
30. Roffe S., Hagai Y., Pines M., Halevy O. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. Exp. Cell Res. 2010, 316:1061-1069.
31. Halevy O., Nagler A., Levi-Schaffer F., Genina O., Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem. Pharmacol. 1996, 52:1057-1063.
32. Pines M., Vlodavsky I., Nagler A. Halofuginone: from veterinary use to human therapy. Drug Dev. Res. 2000, 50:371-378.
33. McGaha T.L., Phelps R.G., Spiera H., Bona C. Halofuginone, an inhibitor of type-collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 2002, 118:461-470.
34. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., Samuni A.M., Felici A., Reiss M., Yarkoni S., Sowers A., Mitchell J.B., Roberts A.B., Russo A. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 2004, 279:15167-15176.
35. Watsky M.A., Weber K.T., Sun Y., Postlethwaite A. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies. Int. Rev. Cell Mol. Biol. 2010, 282:165-192.
36. Klingberg F., Hinz B., White E.S. The myofibroblast matrix: implications for tissue repair and fibrosis. J. Pathol. 2013, 229:298-309.
37. Kramann R., Dirocco D.P., Humphreys B.D. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J. Pathol. 2013, 231:273-289.
38. Sundrud M.S., Koralov S.B., Feuerer M., Calado D.P., Kozhaya A.E., Rhule-Smith A., Lefebvre R.E., Unutmaz D., Mazitschek R., Waldner H., Whitman M., Keller T., Rao A. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009, 324:1334-1338.
39. Ben Dov N., Shefer G., Irintchev A., Wernig A., Oron U., Halevy O. Low-energy laser irradiation affects satellite cell proliferation and differentiation in vitro. Biochim. Biophys. Acta 1999, 1448:372-380.
40. Yaffe D., Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977, 270:725-727.
41. Rosenblatt J.D., Lunt A.I., Parry D.J., Partridge T.A. Culturing satellite cells from living single muscle fiber explants. In Vitro Cell. Dev. Biol. Anim. 1995, 3:773-779.
42. Collins C.A., Zammit P.S. Isolation and grafting of single muscle fibres. Methods Mol. Biol. 2009, 482:319-330.
43. Halevy O., Piestun Y., Allouh M., Rosser B., Rinkevitch Y., Rozenboim R.I., Wleklinski-Lee M., Yablonka-Reuveni Z. The pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewal. Dev. Dyn. 2004, 231:489-502.
44. Spector I., Zilbstein Y., Lavi A., Genin O., Pines M. Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. PLoS One 2012, 7:e41833.
45. SAS J.M.P. Statistics and Graphic Guide, Version 4 2002, SAS Institute Incorporation, Cary, NC.
46. Nakae Y., Stoward P.J., Shono M., Matsuzaki T. Most apoptotic cells in mdx diaphragm muscle contain accumulated lipofuscin. Histochem. Cell Biol. 2001, 115:205-214.
47. Danielsson O., Nilsson C., Lindvall B., Ernerudh J. Expression of apoptosis related proteins in normal and diseased muscle: a possible role for Bcl-2 in protection of striated muscle. Neuromuscul. Disord. 2009, 19:412-417.
48. Sandri M., El Meslemani A.H., Sandri C., Schjerling P., Vissing K., Andersen J.L., Rossini K., Carraro U., Angelini C. Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment?. J. Neuropathol. Exp. Neurol. 2001, 60:302-312.
49. Iwata Y., Katanosaka Y., Arai Y., Shigekawa M., Wakabayashi S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Hum. Mol. Genet. 2009, 18:824-834.
50. Tidball J.G., Villalta S.A. Regulatory interactions between muscle and the immune system during muscle regeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010, 298:R1173-R1187.
51. Zanotti S., Gibertini S., Bragato C., Mantegazza R., Morandi L., Mora M. Fibroblasts from the muscles of Duchenne muscular dystrophy patients are resistant to cell detachment apoptosis. Exp. Cell Res. 2011, 317:2536-2547.
52. Zanotti S., Gibertini S., Mora M. Altered production of extra-cellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatment. Cell Tissue Res. 2010, 339:397-410.
53. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
54. Evans R.A., Tian Y.C., Steadman R., Phillips A.O. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp. Cell Res. 2003, 282:90-100.
55. Serrano A.L., Mann C.J., Vidal B., Ardite E., Perdiguero E., Muñoz-Cánoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr. Top. Dev. Biol. 2011, 96:1167-1201.
56. Allen R.E., Boxhorn L.K. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin like growth factor I, and fibroblast growth factor. J. Cell. Physiol. 1989, 138:311-315.
57. Kollias H.D., McDermott J.C. Transforming growth factor-β and myostatin signaling in skeletal muscle. J. Appl. Physiol. 2008, 104:579-587.
58. Gardner S., Alzhanov D., Knollman P., Kuninger D., Rotwein P. TGF-β inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II. Mol. Endocrinol. 2011, 25:128-137.
59. Zhu S., Goldschmidt-Clermont P.J., Dong C. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ. Res. 2004, 94:617-625.
60. Li X., McFarland D.C., Velleman S. Transforming growth factor-β1-induced satellite cell apoptosis in chickens associated with β1 integrin-mediated focal adhesion kinase activation. Poult. Sci. 2009, 88:1725-1734.
61. Hill M.M., Hemmings B.A. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. 2002, 93:243-251.
62. Parcellier A., Tintignac L.A., Zhuravleva E., Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell. Signal. 2008, 20:21-30.
63. Mourkioti F., Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol. 2005, 26:535-542.
64. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
65. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
66. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
67. Kim M.H., Kay D.I., Rudra R.T., Chen B.M., Hsu N., Izumiya Y., Martinez L., Spencer M.J., Walsh K., Grinnell A.D., Crosbie R.H. Myogenic Akt signaling attenuates muscular degeneration, promotes myofiber regeneration and improves muscle function in dystrophin-deficient mdx mice. Hum. Mol. Genet. 2011, 20:1324-1338.
68. Liu A.H., Cao Y.N., Liu H.T., Zhang W.W., Liu Y., Shi T.W., Jia G.L., Wang X.M. DIDS attenuates staurosporine-induced cardiomyocyte apoptosis by PI3K/Akt signaling pathway: activation of eNOS/NO and inhibition of Bax translocation. Cell. Physiol. Biochem. 2008, 22:177-186.
69. Ostrovsky O., Bengal E. The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J. Biol. Chem. 2003, 278:21221-21231.